ストックスクリーナーアプリを入手
80.01
1.06%
0.84
アフターアワーズ：
80.87
0.86
+1.07%
Cytokinetics Inc (CYTK) 最新ニュース
Cytokinetics Stock Rockets 18% With 7-Day Winning Streak - Trefis
Cytokinetics stock reaches 52-week high at 80.25 USD - Investing.com
Cytokinetics stock reaches 52-week high at 80.25 USD By Investing.com - Investing.com Canada
Cytokinetics Stock 6-Day Winning Spree: Stock Climbs 17% - Trefis
Cytokinetics (CYTK) RBC Capital Markets Global Healthcare Conference 2026 Summary - Quartr
Certain Options of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 21-JUN-2026. - marketscreener.com
Cytokinetics Inc (CYTK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytokinetics Inc (CYTK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytokinetics Inc (CYTK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cytokinetics Inc (CYTK) Institutional Confidence - TradingKey
Cytokinetics Inc (CYTK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Inc (CYTK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytokinetics Inc (CYTK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytokinetics Inc (CYTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock? - Yahoo Finance
CYTK Reiterates by Needham -- Price Target Maintained at $102 - GuruFocus
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $83 to $103 - Moomoo
Cytokinetics stock rating reaffirmed at Outperform by RBC Capital - Investing.com Australia
Cytokinetics shares climb as investors refocus on MYQORZO launch momentum and expansion runway - Quiver Quantitative
Edgewise heart drug passes key trial test - BioPharma Dive
Edgewise heads to phase III with solid EDG-7500 data in HCM - BioWorld News
CYTK News | CYTOKINETICS INC (NASDAQ:CYTK) - ChartMill
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares in open market trade - Stock Titan
Cytokinetics, Inc. (CYTK) Stock Analysis: Tapping into a Potential 49% Upside in the Biotech Sector - DirectorsTalk Interviews
Cytokinetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $106.58, Implies 52% Upside - TradingView
Monashee Investment Management LLC Sells 25,000 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Acquired by GW&K Investment Management LLC - MarketBeat
Cytokinetics (CYTK) Slips Amid Biotech Volatility as Stock Tests Key Support LevelsSpring Pattern - newsline.com
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics EVP Malik sells $237,930 in shares By Investing.com - Investing.com Nigeria
Cytokinetics EVP Malik sells $237,930 in shares - Investing.com India
Cytokinetics (CYTK) EVP exercises options and sells 3,500 shares - Stock Titan
Nonprofits can seek up to $20K from Cytokinetics for health equity - Stock Titan
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK) - Yahoo Finance
807,070 Shares in Cytokinetics, Incorporated $CYTK Acquired by Norges Bank - MarketBeat
Cytokinetics, Inc. (CYTK) Stock Analysis: A Promising Biotech Player with Potential 46.47% Upside - DirectorsTalk Interviews
Cytokinetics, Incorporated $CYTK Stake Trimmed by TD Asset Management Inc - MarketBeat
Total liabilities & shareholders' equities of Cytokinetics, Incorporated – XETR:KK3A - TradingView
CYTK Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesEarnings Power Value - newsline.com
Long term debt to total assets ratio of Cytokinetics, Incorporated – XETR:KK3A - TradingView
ETFs Investing in Cytokinetics, Incorporated Stocks - TradingView
Cytokinetics, Incorporated Trade Ideas — XETR:KK3A - TradingView
Cytokinetics prices $700 million stock offering at $71 per share - Investing.com
Truist raises Cytokinetics stock price target on positive trial data - Investing.com
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
Cytokinetics prices public offering of 9.8 mln shares at $71/share - marketscreener.com
Cytokinetics Inc (CYTK) News, Articles, Events & Latest Updates - Stocktwits
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report? - Yahoo Finance
BNP Paribas Financial Markets Purchases 332,397 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia
Cytokinetics director Parshall sells $370,400 of CYTK stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokineti - GuruFocus
Cytokinetics EVP Andrew Callos sells $1.11m in stock By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
0.48%
大文字化:
|
ボリューム (24 時間):